R T Heelan

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

35h-index5.3kcitations79works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(28), Lung Cancer Diagnosis and Treatment(18), Lung Cancer Research Studies(13), Medical Imaging and Pathology Studies(12), Gastric Cancer Management and Outcomes(9)

Publications79 total

A phase II study to determine if sensory neuropathy of nab-paclitaxel can be reduced by prolonging infusion in patients with non-small cell lung cancer (NSCLC)
Journal of Clinical Oncology·2007· 2 cited
Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial
Journal of Clinical Oncology·2007· 25 cited
Erratum: Radiographic imaging of bronchioloalveolar carcinoma: Screening, patterns of presentation and response assessment (Journal of Thoracic Oncology (2006) 1, (S20-S26))
2007· 8 cited
Phase I/II study of ABI-007 as first line chemotherapy in advanced non-small cell lung cancer (NSCLC)
Journal of Clinical Oncology·2006· 3 cited
Prospective trial with preoperative gefitinib to correlate lung cancer response with <i>EGFR</i> exon 19 and 21 mutations and to select patients for adjuvant therapy
Journal of Clinical Oncology·2006· 17 cited
O-123 A prospective study to correlate EGFR mutations with gefitinib response in early stage NSCLC
Lung Cancer·2005
EGFR mutation, immunohistochemistry (IHC) and chromogenic <i>in situ</i> hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC
Journal of Clinical Oncology·2005· 10 cited
A prospective study to correlate EGFR mutations with gefitinib response
Journal of Clinical Oncology·2005· 5 cited
Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Journal of Clinical Oncology·2005· 24 cited
Clinical characteristics and natural history of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (<i>EGFR</i>) mutations treated with erlotinib or gefitinib
Journal of Clinical Oncology·2005· 3 cited
Induction chemotherapy, extrapleural pneumonectomy (EPP), and adjuvant hemithoracic radiation are feasible and effective for locally advanced malignant pleural mesothelioma (MPM)
Journal of Clinical Oncology·2004· 3 cited
Induction chemotherapy, extrapleural pneumonectomy (EPP), and adjuvant hemithoracic radiation are feasible and effective for locally advanced malignant pleural mesothelioma (MPM)
Journal of Clinical Oncology·2004· 6 cited
Weekly high-dose erlotinib in patients with non-small cell lung cancer (NSCLC): A phase I/II study
Journal of Clinical Oncology·2004
Weekly high-dose erlotinib in patients with non-small cell lung cancer (NSCLC): A phase I/II study
Journal of Clinical Oncology·2004· 5 cited
54 The epidermal growth factor receptor tyrosine kinase inhibitor, eriotinib (Tarceva TM, OSI-774), is an active agent in bronchioloalveolar carcinoma (BAC) and its variants: interim results of a phase II trial
European Journal of Cancer Supplements·2003· 14 cited
A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus.
PubMed·2001· 136 cited
Randomized phase II trial comparing trastuzumab plus weekly docetaxel versus trastuzumab plus weekly paclitaxel in previously untreated advanced non-small cell lung cancer (NSCLC)
Lung Cancer·2000· 5 cited
The radiographic presentation of large cell neuroendocrine carcinoma of the lung
Lung Cancer·2000
Pilot trial of ZD1839 (IressaTM), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC)
Lung Cancer·2000· 20 cited
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer
Annals of Oncology·2000· 63 cited
page 1 of 4Next →

Frequent Co-authors

Mark G. Kris(13), David M. Panicek(9), David P. Kelsen(8), Manjit S. Bains(8), James F. Caravelli(7), D. P. Kelsen(5), Nael Martini(4), Michael Burt(4), V.A. Miller(4), Valerie W. Rusch(3), Robert J. Motzer(3), H.W. Herr(3), Richard J. Gralla(3), Antonella Surbone(3), George J. Bosl(3), Margaret Barton‐Burke(3), Lawrence H. Schwartz(3), Lee M. Krug(3), V. A. Miller(3), Barbara Pizzo(3)